{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:25:43Z","timestamp":1787682343741,"version":"build-2784847793"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pbb.2020.172996","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T09:56:29Z","timestamp":1594547789000},"page":"172996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development"],"prefix":"10.1016","volume":"196","author":[{"given":"A.","family":"Biggerstaff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kivell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Y.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.K.","family":"Golani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sharmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pbb.2020.172996_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.109.158303","article-title":"Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2\/3 subtypes","volume":"332","author":"Ator","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2020.172996_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000435939","article-title":"Generalized anxiety disorder and pain","volume":"30","author":"Bandelow","year":"2015","journal-title":"Mod. Trends Pharmacopsychiat."},{"issue":"2 Suppl","key":"10.1016\/j.pbb.2020.172996_bb0015","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Phys."},{"issue":"1","key":"10.1016\/j.pbb.2020.172996_bb0020","first-page":"117","article-title":"Improvements in the pharmacological profile of diazepam by KRM-II-81, an imidizodiazepine positive allosteric modulator of \u03b12\/3-containing GABAA receptors: preclinical data predict enhanced efficacy for epilepsy, chronic pain, anxiety, and depression","volume":"2","author":"Cerne","year":"2019","journal-title":"Pharmaceut. Sci. Biomed. Anal. J."},{"issue":"2","key":"10.1016\/j.pbb.2020.172996_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/jpet.119.259408","article-title":"The opioid crisis and the future of addiction and pain therapeutics","volume":"371","author":"Coussens","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"23","key":"10.1016\/j.pbb.2020.172996_bb0045","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1111\/bph.14055","article-title":"The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice","volume":"174","author":"Crowe","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2020.172996_bb9010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2020.172996_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0022-3565(25)12039-9","article-title":"Intrathecal baclofen and muscimol, but not midazolam, are antinociceptive using the rat-formalin model","volume":"275","author":"Dirig","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2020.172996_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(06)54001-3","article-title":"The role of GABA in the mediation and perception of pain","volume":"54","author":"Enna","year":"2006","journal-title":"Adv. Pharmacol."},{"issue":"46","key":"10.1016\/j.pbb.2020.172996_bb0060","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1523\/JNEUROSCI.2301-16.2016","article-title":"Functional synaptic integration of forebrain GABAergic precursors into the adult spinal cord","volume":"36","author":"Etlin","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2020.172996_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuroscience.2015.09.038","article-title":"Tolerance to the sedative and anxiolytic effects of diazepam is associated with different alterations of GABAA receptors in rat cerebral cortex","volume":"310","author":"Ferreri","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2020.172996_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2017.03.001","article-title":"Pharmacological and antihyperalgesic properties of the novel \u03b12\/3 preferring GABAA receptor ligand MP-III-024","volume":"131","author":"Fischer","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2020.172996_bb0075","doi-asserted-by":"crossref","first-page":"134801","DOI":"10.1016\/j.neulet.2020.134801","article-title":"Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor \u03b11 subunit gene via L-type voltage-gated calcium channel activation in rat cerebrocortical neurons","volume":"721","author":"Foitzick","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pbb.2020.172996_bb0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF02244987","article-title":"Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists","volume":"114","author":"Ginski","year":"1994","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pbb.2020.172996_bb0085","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/j.pain.0000000000001267","article-title":"A randomised, placebo-controlled clinical trial with the \u03b12\/3\/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain","volume":"159","author":"Gurrell","year":"2018","journal-title":"Pain"},{"issue":"1\u20132","key":"10.1016\/j.pbb.2020.172996_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(84)90197-3","article-title":"Effects of intrathecally administered THIP, baclofen and muscimol on nociceptive threshold","volume":"103","author":"Hammond","year":"1984","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.pbb.2020.172996_bb0095","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0310057X1103900505","article-title":"Acute pain management in opioid-tolerant patients: a growing challenge","volume":"39","author":"Huxtable","year":"2011","journal-title":"Anaesth. Intensive Care"},{"issue":"3","key":"10.1016\/j.pbb.2020.172996_bb0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/15360288.2011.596922","article-title":"Anxiety disorders: differential diagnosis and their relationship to chronic pain","volume":"25","author":"Jordan","year":"2011","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"10.1016\/j.pbb.2020.172996_bb0105","first-page":"1","article-title":"Chemothrapy-induced peripheral neuropathy: causative agents, preventative strategies, and treatment approaches","author":"Kachrani","year":"2020","journal-title":"J. Pain Palliat. Care Pharmacother."},{"issue":"3","key":"10.1016\/j.pbb.2020.172996_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(25)06888-7","article-title":"Tolerance to, and dependence on, some non-opiate psychotropic drugs","volume":"23","author":"Kalant","year":"1971","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2020.172996_bb0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuroscience.2017.01.021","article-title":"Neonatal bladder inflammation induces long-term visceral pain and altered responses of spinal neurons in adult rats","volume":"346","author":"Kannampalli","year":"2017","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pbb.2020.172996_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pain.2008.10.015","article-title":"Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice","volume":"141","author":"Knabl","year":"2009","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.pbb.2020.172996_bb0125","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3346\/jkms.2013.28.2.308","article-title":"Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain","volume":"28","author":"Lee","year":"2013","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.pbb.2020.172996_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/JPR.S224478","article-title":"The antiallodynic effect of nefopam on vincristine-induced neuropathy in mice","volume":"13","author":"Lee","year":"2020","journal-title":"J. Pain Res."},{"key":"10.1016\/j.pbb.2020.172996_bb0135","article-title":"Comparison of chemotherapy effects on mechanical sensitivity and food-maintained operant responding in male and female rats","author":"Legakis","year":"2019","journal-title":"Behav. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2020.172996_bb0140","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschemneuro.6b00447","article-title":"Antinociceptive effects of a novel \u03b12\/\u03b13-subtype selective GABAA receptor positive allosteric modulator","volume":"8","author":"Lewter","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2020.172996_bb0145","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.lfs.2005.08.002","article-title":"Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying","volume":"78","author":"Li","year":"2006","journal-title":"Life Sci."},{"issue":"20","key":"10.1016\/j.pbb.2020.172996_bb0150","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1055\/s-0037-1610211","article-title":"Improved synthesis of anxiolytic, anticonvulsant and antinociceptive \u03b12\/\u03b13-GABA(A)ergic receptor subtype selective ligands as promising agents to treat anxiety, epilepsy, as well as neuropathic pain","volume":"50","author":"Li","year":"2018","journal-title":"Synthesis"},{"issue":"32","key":"10.1016\/j.pbb.2020.172996_bb0155","first-page":"2492","article-title":"Expression of gamma-aminobutyric acid type A receptor \u03b12 subunit in the dorsal root ganglion of rats with sciatic nerve injury","volume":"7","author":"Lian","year":"2012","journal-title":"Neural Regen. Res."},{"issue":"24","key":"10.1016\/j.pbb.2020.172996_bb0160","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1523\/JNEUROSCI.0159-14.2014","article-title":"Gephyrin clusters are absent from small diameter primary afferent terminals despite the presence of GABA(A) receptors","volume":"34","author":"Lorenzo","year":"2014","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.pbb.2020.172996_bb0165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: a review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pbb.2020.172996_bb0170","doi-asserted-by":"crossref","DOI":"10.1007\/s12640-020-00176-2","article-title":"Behavioral, electrophysiological, and histological characterization of a new rat model for neoadjuvant chemotherapy-induced neuropathic pain: therapeutic potential of duloxetine and allopregnanolone concomitant treatment","author":"Matta","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.pbb.2020.172996_bb0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.pbb.2020.172996_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pbb.2018.04.009","article-title":"An antidepressant-related pharmacological signature for positive allosteric modulators of \u03b12\/3-containing GABAA receptors","volume":"170","author":"Methuku","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2020.172996_bb0195","doi-asserted-by":"crossref","unstructured":"Moerke MJ, Li G, Golani LK, Cook J, Negus SS. Effects of the \u03b12\/\u03b13-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam. Behav. Pharmacol.. 2019 Jan 10.","DOI":"10.1097\/FBP.0000000000000464"},{"issue":"10","key":"10.1016\/j.pbb.2020.172996_bb0200","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis","volume":"16","author":"Nee","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.pbb.2020.172996_bb0205","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bph.14119","article-title":"Pharmacology in translation; the preclinical and early clinical profile of the novel \u03b12\/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865","volume":"175","author":"Nickolls","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2020.172996_bb0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14728214.2016.1257605","article-title":"Emerging drugs for diabetic peripheral neuropathy and neuropathic pain","volume":"21","author":"Papanas","year":"2016","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"6","key":"10.1016\/j.pbb.2020.172996_bb0220","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/ejp.1002","article-title":"The analgesic and anti-inflammatory effects of Salvinorin A analogue \u03b2-tetrahydropyran Salvinorin B in mice","volume":"21","author":"Paton","year":"2017","journal-title":"Eur. J. Pain"},{"issue":"17","key":"10.1016\/j.pbb.2020.172996_bb0225","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1002\/cne.23129","article-title":"Selective distribution of GABA(A) receptor subtypes in mouse spinal dorsal horn neurons and primary afferents","volume":"520","author":"Paul","year":"2012","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.pbb.2020.172996_bb0235","doi-asserted-by":"crossref","unstructured":"Poe MM., Kashi R. Methuku KR, Li G., Teske, K.A., Stafford, D.C., Arnold, L.A., Cramer, J.W., Jones T.M., McDermott, J.S., Witkin, J.M., Cook, Schkeryantz, J.M. 2016 Synthesis and characterization of a novel GABAA receptor ligand, 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (KRM-II-81), that combines exceptional drug stability, pharmacokinetics, and anxiolytic efficacy. J. Med. Chem.. 59, 10800\u201310806.","DOI":"10.1021\/acs.jmedchem.6b01332"},{"issue":"2","key":"10.1016\/j.pbb.2020.172996_bb0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/02791072.2012.684621","article-title":"Chronic pain and addiction: challenging co-occurring disorders","volume":"44","author":"Pohl","year":"2012","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pbb.2020.172996_bb0245","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","volume":"6","author":"Ralvenius","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pbb.2020.172996_bb0260","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/jm801652d","article-title":"Antiseizure activity of novel \u03b3-aminobutyric acid A receptor subtype-selective benzodiazepine analogues in mice and rat models","volume":"52","author":"Rivas","year":"2009","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pbb.2020.172996_bb0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0149-7634(85)90038-7","article-title":"Time course for development of benzodiazepine tolerance and physical dependence","volume":"9","author":"Rosenberg","year":"1985","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.pbb.2020.172996_bb0270","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.mcna.2013.07.005","article-title":"Patients with chronic pain","volume":"97","author":"Salama-Hanna","year":"2013","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.pbb.2020.172996_bb0275","doi-asserted-by":"crossref","first-page":"100035","DOI":"10.1016\/j.ynpai.2019.100035","article-title":"Voluntary exercise reduces both chemotherapy-induced neuropathic nociception and deficits in hippocampal cellular proliferation in a mouse model of paclitaxel-induced peripheral neuropathy","volume":"6","author":"Slivicki","year":"2019","journal-title":"Neurobiol. Pain"},{"key":"10.1016\/j.pbb.2020.172996_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113121","article-title":"Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems","volume":"324","author":"Staff","year":"2020","journal-title":"Exp. Neurol."},{"issue":"20","key":"10.1016\/j.pbb.2020.172996_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015425","article-title":"Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review","volume":"98","author":"Stoicea","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pbb.2020.172996_bb0290","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature08758","article-title":"Neural bases for addictive properties of benzodiazepines","volume":"463","author":"Tan","year":"2010","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.pbb.2020.172996_bb0295","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","article-title":"Untangling the complexity of opioid receptor function","volume":"43","author":"Valentino","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"30","key":"10.1016\/j.pbb.2020.172996_bb0300","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1523\/JNEUROSCI.1067-04.2004","article-title":"Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice","volume":"24","author":"van Rijnsoever","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2020.172996_bb9015","article-title":"Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?","volume":"2012","author":"Vinkers","year":"2012","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2020.172996_bb0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coph.2004.08.006","article-title":"GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?","volume":"5","author":"Wafford","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pbb.2020.172996_bb0315","first-page":"CD012592","article-title":"Opioids for cancer pain - an overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pbb.2020.172996_bb0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2017.04.009","article-title":"Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for \u03b12\/3-containing GABAA receptors","volume":"157","author":"Witkin","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2020.172996_bb0325","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuropharm.2018.05.006","article-title":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy","volume":"137","author":"Witkin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2020.172996_bb0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.02.013","article-title":"The \u03b12,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats","volume":"180","author":"Witkin","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.pbb.2020.172996_bb0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.119.260968","article-title":"The positive allosteric modulator of \u03b12\/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury","volume":"372","author":"Witkin","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2020.172996_bb0340","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lfs.2017.09.033","article-title":"Research progress of mechanisms and drug therapy for neuropathic pain","volume":"190","author":"Yan","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2020.172996_bb0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.apha.2014.11.007","article-title":"Restoring the spinal pain gate: GABA(A) receptors as targets for novel analgesics","volume":"73","author":"Zeilhofer","year":"2015","journal-title":"Adv. Pharmacol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720302367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720302367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:39:19Z","timestamp":1758775159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305720302367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":61,"alternative-id":["S0091305720302367"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172996","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"172996"}}